How does 5VA's PB Ratio compare to its peers?

5VA is expensive based on its Price-To-Book Ratio (3.2x) compared to the peer average (2.9x).

How does 5VA's PB Ratio compare vs other companies in the DE Biotechs Industry?

5VA is expensive based on its Price-To-Book Ratio (3.2x) compared to the European Biotechs industry average (2.4x).

What is 5VA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 5VA's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 5VA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 5VA's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Vaxcyte (MUN:5VA) - Stock Price, News & Analysis

5VA Stock Overview

A clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. More details

5VA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 4.5% per year for the next 3 years

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Vaxcyte, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€821.0m

Heidelberg Pharma

XTRA:HPHA

€101.1m

Sartorius

XTRA:SRT3

€12.8b

Price History & Performance

Summary of all time highs, changes and price drops for Vaxcyte
Historical stock prices
Current Share Price	US$100.00
52 Week High	US$100.00
52 Week Low	US$62.00
Beta	1.01
11 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	140.91%

Recent updates

Shareholder Returns

	5VA	DE Biotechs	DE Market
7D	0%	0.8%	-1.3%
1Y	n/a	-17.5%	7.4%

Return vs Industry: Insufficient data to determine how 5VA performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 5VA performed against the German Market.

Price Volatility

Is 5VA's price volatile compared to industry and market?
5VA volatility
5VA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 5VA's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 5VA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	254	Grant Pickering	vaxcyte.com

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Vaxcyte, Inc. Fundamentals Summary

How do Vaxcyte's earnings and revenue compare to its market cap?
5VA fundamental statistics
Market cap	€10.58b
Earnings (TTM)	-€487.44m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-21.7x

P/E Ratio

Is 5VA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
5VA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$75.00m
Gross Profit	-US$75.00m
Other Expenses	US$432.65m
Earnings	-US$507.65m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-4.07
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 5VA perform over the long term?

See historical performance and comparison

5VA Stock Overview

Risk Analysis

Vaxcyte, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:FYB

€821.0m

XTRA:HPHA

€101.1m

XTRA:SRT3

€12.8b

Price History & Performance

Recent News & Updates

Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Recent updates

Vaxcyte, Inc. Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion.

New major risk - Revenue and earnings growth

Vaxcyte, Inc. has filed a Follow-on Equity Offering.

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024

New major risk - Revenue and earnings growth

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.

Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer

Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise

Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases

Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults

New major risk - Shareholder dilution

Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults

Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023

High number of new directors

High number of new directors

Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

Vaxcyte, Inc. Announces Executive Appointments

Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults

High number of new directors

Shareholder Returns

Price Volatility

About the Company

Vaxcyte, Inc. Fundamentals Summary

0.0x

-21.7x

Earnings & Revenue